Why choose the HepaRG™ cell model for NAFLD investigation?
Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease worldwide, is rapidly becoming the predominant cause of end-stage liver disease and a leading indication for liver transplantation.
25 Nov 2021
SaferWorldbyDesign: Trusted reproducible evidence supporting data-driven decisions
This blog post presents a collection of perspectives that elaborate our vision of reliable and reproducible science supporting product and risk assessment as presented by us this year at the Precision Health conference co-organized by MCBIOS and MAQC.
23 Oct 2021
Evaluating the skin sensitisation potential of a squaric acid
The SaferSkin™ Sensitization application implements three well-adopted defined approaches to perform an integrated analysis of the OECD-approved in vitro tests (DPRA, KeratinoSens™, h-CLAT) for assessment of skin sensitisation potential.
26 Aug 2021
OECD acceptance of Test Guideline 497 (TG 497)
The recent OECD acceptance of TG 497 for defined approaches for skin sensitization marks an important milestone.
27 Jul 2021
Provision of HepaRG™ on SaferWorldbyDesign
HepaRG™ has been manufactured and distributed for many years by Biopredic International, now part of Wepredic. We realized in recent years the increasing need for the development of HepaRG™ infrastructure and services to keep up with the increasing requirements of the HepaRG™ research community and requests from our customers.
24 Jun 2021
Dynamic gene expression profiling of the HepaRG™ cell line
A better molecular characterization of a cell line is a prerequisite for well-planned, educated, and targeted experimentation.
29 Apr 2021
Working as a Community on Data Integrity from Research through to Practice
An important commitment we are making is to ensure data integrity across the journey from research to practice, from case study work to service execution, from study planning through data generation to downstream consumption.
2 Mar 2021
High-throughput prediction of human organ toxicity
This innovative method (Su et al. 2016) was awarded with the Lush Science Price 2016 and combines cell-based assays with bioinformatics. The method predicts specifically toxicity to renal proximal tubular cells, which are one of the main targets for chemical-induced toxicity in the kidney.
29 Jan 2021
HepaRG™ ability to predict drug-cholestatic liability
Drug-induced liver injury (DILI) accounts for more than 50% of acute liver failure and constitutes therefore a major concern for the pharmaceutical industry in drug pre-and post-marketing scenarios.
29 Jan 2021
HepaRG™ goes digital
For many years HepaRG™ has provided a valuable liver cell line for research applications.
10 Nov 2020
SaferWorldbyDesign COVID-19 Data Initiative
Data is the gold of scientific prospecting, whether supporting research publications in academia or product development in industry.
21 May 2020
Launch of the EU-ToxRisk Commercial Platform
The EU-ToxRisk Commercialisation Platform was launched at the EU-ToxRisk Stakeholder meeting in Egmond, the Netherlands on 12 February.
2 Apr 2020
Integrated Approaches to solving Skin Safety Assessment problems
Skin safety is one of the most important goals of the consumer products industry.
15 Mar 2020
SBX’s Taxila™ adds more power to SaferWorldbyDesign
Taxila™ is a platform that aggregates the tons of data produced every day in natural text and converts it to actionable insights.
4 Dec 2019
Improved skin sensitisation safety assessment
Swiss firm TEMAS believes that progress only happens when people work together in networks, crossing the boundaries of specialist fields.
30 Sep 2019
Why Biopredic and Eurosafe join SaferWorldbyDesign
Dr. Christophe Chesné, the founder and CEO of Biopredic International and Eurosafe, explains why his two companies are founding partners of SaferWorldbyDesign.
27 Sep 2019
Making AI available to companies, large and small
Co-founder and CEO Tom Bell explains why Vertex Laboratories is a founding member of SaferWorldbyDesign.
13 Sep 2019